Search Results

You are looking at 321 - 330 of 2,880 items for :

  • Refine by Access: All x
Clear All
Full access

HSR20-076: Provider Versus Patient Reported Outcomes (PROs) in Colorectal Cancer (CRC) Patients (pts) Undergoing Systemic Therapy (Ctx): A Real World Experience

Sonali Agrawal, Caitlin R. Meeker, Sandeep Aggarwal, Elizabeth A. Handorf, Sunil Adige, Efrat Dotan, Crystal S. Denlinger, William H. Ward, Jeffrey M. Farma, and Namrata Vijayvergia

Full access

Toward Less-Invasive Management of Early-Stage Breast Cancer

Amy Cyr

modality. This modality allows for more individualized, flexible delivery of radiation and appears to result in less fat necrosis; however, formal data on these and oncologic outcomes are lacking. In a study presented at the ASTRO 2014 Annual Meeting, after

Full access

In the Age of Novel Therapies, What Defines High-Risk Multiple Myeloma?

Ashraf Badros

% of patients survive longer than 10 years, irrespective of therapy. 1 , 2 Genetic variations among myeloma cells appear to underlie much of the heterogeneity in clinical outcomes. Several groups have reported on the prognostic capability of genetic

Full access

Monitoring Minimal Residual Disease in Acute Myeloid Leukemia: Ready for Prime Time?

Farhad Ravandi and Jeffrey L. Jorgensen

molecular abnormalities both in cytogenetically normal and abnormal AML, they are by no means absolute in predicting the outcome. 5 Therefore, more than 35% of patients with “favorable risk” cytogenetics experience relapse, and despite better identification

Full access

Emerging Therapies in the Treatment of Bladder Cancer

Presented by: Arlene O. Siefker-Radtke

stable disease or better after undergoing frontline platinum-based chemotherapy. This recent category 1 recommendation provides clinicians with more options to improve long-term outcomes in the setting of metastatic urothelial cancer. Targeted

Full access

Monitoring Chronic Myelogenous Leukemia in the Age of Tyrosine Kinase Inhibitors

Jerald P. Radich and Vivian Oehler

clinical outcome in chronic myeloid leukaemia . Br J Haematol 2003 ; 120 : 990 – 999 . 23. Branford S Rudzki Z Harper A . Imatinib produces significantly superior molecular responses compared with interferon alfa plus cytarabine in patients

Full access

Management of Primary Central Nervous System Lymphoma

Francois G. El Kamar and Lauren E. Abrey

outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments . J Clin Oncol 2002 ; 20 : 231 – 236 . 21 Ferreri AJ Blay JY Reni M . Prognostic scoring system for primary

Full access

Head and Neck Cancers: Advantages of Advanced Radiation Therapy and Importance of Supportive Care

Sharon Spencer

look at outcomes,” she noted at the NCCN 23rd Annual Conference, “we are seeing improvement. But we can do better.” H&N squamous cell carcinoma (HNSCC) is a heterogeneous disease, encompassing a variety of tumors that originate in the hypopharynx

Full access

Exocrine Pancreas Cancer and Thromboembolic Events: A Systematic Literature Review

Andrew S. Epstein and Eileen M. O'Reilly

pancreatic cancer Analyze recommendations for primary prophylaxis against thromboembolism among patients with pancreatic cancer Assess the best treatment for thromboembolism among patients with pancreatic cancer Evaluate outcomes improved

Full access

NCCN Task Force Report: Molecular Markers in Leukemias and Lymphomas

Jerald P. Radich, Andrew D. Zelenetz, Wing C. Chan, Carlo M. Croce, Myron S. Czuczman, Harry P. Erba, Sandra J. Horning, Jane Houldsworth, B. Douglas Smith, David S. Snyder, Hema M. Sundar, Meir Wetzler, and Jane N. Winter

with imatinib (IM) [abstract] . Blood 2008 ; 112 : Abstract 186 . 16 Kantarjian H O’Brien S Talpaz M . Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure . Cancer 2007